What's Happening?
Amplitude Vascular Systems (AVS), a medical device company recently acquired by Stryker, has enrolled the first patient in its first-in-human study for Pulsatile Intravascular Lithotripsy (PIVL) therapy. This study, known as POWER CAD I, aims to evaluate
the feasibility of the Pulse IVL System in treating patients with moderate to severely calcified coronary arterial disease. The initial procedure was conducted by Dr. Jithendra Somaratne at Auckland City Hospital in New Zealand. The study plans to enroll up to 15 subjects across four facilities in Australia and New Zealand, with primary endpoints assessed at 30 days. The Pulse IVL System is designed to deliver treatment efficiently and is currently an investigational device not yet cleared for commercial distribution.
Why It's Important?
This development is significant as it represents a potential advancement in the treatment of calcified coronary artery disease, a condition that can complicate stent placement and other interventions. The use of intravascular lithotripsy, which employs a unique hydraulic mechanism, could offer a new therapeutic option for patients with this challenging condition. If successful, the study could pave the way for broader application of this technology, potentially improving patient outcomes and expanding treatment options in the field of interventional cardiology. The involvement of Stryker, a major player in medical technologies, underscores the potential impact and commercial interest in this innovative approach.
What's Next?
Following the initial enrollment, the study will continue to recruit additional patients to reach its target of 15 participants. The results of the POWER CAD I study will be crucial in determining the next steps for the Pulse IVL System, including potential regulatory approvals and commercial distribution. If the study demonstrates positive outcomes, it could lead to further clinical trials and eventual integration into standard treatment protocols for coronary artery disease. Stakeholders, including healthcare providers and patients, will be closely monitoring the study's progress and results.
